Faculty, Staff and Student Publications
Publication Date
2-6-2025
Journal
The Oncologist
Abstract
Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC.
Keywords
Humans, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Immunotherapy, ErbB Receptors, Mutation, Molecular Targeted Therapy, Biomarkers, Tumor, clinical decision-making, controversies, unanswered questions, lung cancer diagnosis, lung cancer treatment, lung cancer management
DOI
10.1093/oncolo/oyae228
PMID
39237103
PMCID
PMC11883156
PubMedCentral® Posted Date
9-5-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons